Why do billionaires get booed? How does Facebook end up with sensitive health data? And does biotech have a dribbling problem?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Katie Palmer, STAT’s health tech correspondent, joins us to explain how the explosive popularity of telehealth is putting sensitive patient information into the hands of Facebook, TikTok, and other big tech firms. We also discuss the latest news in the life sciences, including highlights from a big hematology conference, a disastrous biotech IPO, and the downside of being a good quote.
Sponsored insight by GENENTECH, A MEMBER OF THE ROCHE GROUP
Pursuing a better future for people living with hematologic disorders
Hematologic disorders, including non-Hodgkin’s lymphomas and others, significantly impact the lives of millions of Americans. Innovative immunotherapies and other novel medicines have the potential to offer hope to these individuals for a longer life and reduce burdens at various stages of their treatment journey.
Scientists at Genentech are pursuing therapeutic innovations to improve outcomes for people with hematologic disorders and rethinking what is possible when it comes to standards of care and the patient experience. Learn more about how research has made important strides in treating various types of blood diseases.
No comments